A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

NCT01434186 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Placebo matching with Saxagliptin
DRUG: Metformin IR
DRUG: Metformin XR
DRUG: Saxagliptin

Sponsor

AstraZeneca

Collaborators

[object Object]